Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies
Status:
Completed
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
Phase I study to define the safety profile and pharmacokinetic parameters of SGN-35 in
patients with relapsed/refractory CD30-positive hematologic malignancies. This is a
single-arm, open-label, Phase I dose escalation study designed to define the MTD, PK,
immunogenicity and anti-tumor activity of SGN-35 in patients with relapsed/refractory
CD30-positive hematologic malignancies.